

Pending US Cases:

PF112U1 - can file the 11-30 response. Refer back.

PF112P4 - only needs the most recent Alitalo Dec. - can be filed in the response that is going out in Nov.

PF112/D2C1

PF112/P6

PF112P2D1/D1

PF112P2D2/P2D2

PF112P3/D1C1

PF112P3/P3US

IDS References:

| | US Pat No. | | Name | Date of Pub. |
|----|-----------------|--------------|---|--------------|
| 1 | 5,326,695 | | Andersson et al. | 07-05-1994 |
| 2 | 5,073,492 | | Chen et al. | 12-17-1991 |
| 3 | 5,607,918 | | Eriksson et al. | 03-04-1997 |
| 4 | 5,840,693 B1 | | Eriksson et al. | 11-24-1999 |
| 5 | 5,240,848 | | Keck et al. | 08-31-1993 |
| 6 | 5,283,354 | | Lemischka | 02-01-1994 |
| 7 | 5,633,147 | | Meissner et al. | 05-27-1999 |
| 8 | 5,234,908 | | Szabo et al. | 08-10-1993 |
| 9 | 5,861,301 B1 | | Terman et al. | 01-19-1999 |
| 10 | 5,194,596 | | Tischer et al. | 03-16-1993 |
| 11 | 5,219,739 | | Tischer et al. | 06-15-1993 |
| 12 | 08/340011 | | | 11/1994 |
| 13 | 08/510133 | | | 08/1995 |
| 14 | 08/585895 | | | 01/1996 |
| 15 | 08/601132 | | | 02/1996 |
| 16 | 08/671573 | | | 06/1996 |
| 17 | 60/003491 | | | 09/1995 |
| 18 | 08/554374 | | | 11/1995 |
| | | | | |
| | | | | |
| | Foreign Pat No. | Coun | Name | Date of Pub. |
| 19 | 92/14748 | PCT | American Cyanamid Co. | 09-03-1992 |
| 20 | 0-476983 A1 | EP | Bayne, et al. | 03-25-1992 |
| 21 | 0-506477 A1 | EP | Bayne, et al. | 09-30-1992 |
| 22 | 98/49300 | PCT | Collateral Therapeutics | 11-05-1998 |
| 23 | 710696 | AU | Genentech, Inc. | 09-30-1999 |
| 24 | 97/09427 | PCT | Genentech, Inc. | 03-13-1997 |
| 25 | 94/3464 | South Africa | Human Genome Sciences, Inc. | 01-31-1996 |
| 26 | 99/46364 | PCT | Human Genome Sciences, Inc. | 09-16-1999 |
| 27 | 96/39515 | PCT | Human Genome Sciences, Inc. | 12-12-1996 |
| 28 | 96/05856 | PCT | Human Genome Sciences, Inc. | 02-29-1996 |
| 29 | 95/24414 | PCT | Human Genome Sciences, Inc. | 09-14-1995 |
| 30 | 95/19985 | PCT | Human Genome Sciences, Inc. | 07-27-1995 |
| 31 | 98/06844 | PCT | Human Genome Sciences, Inc. | 02-19-1998 |
| 32 | 97/17442 | PCT | Immunex Corporation | 05-15-1997 |
| 33 | 98/33917 | PCT | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. | 06-08-1998 |
| 34 | 99/08522 | PCT | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. | 02-25-1999 |
| 35 | 98/07832 | PCT | Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy | 02-26-1998 |
| 36 | 98/56936 | PCT | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | 12-17-1998 |
| 37 | 99/21590 | PCT | Merck & Co. | 05-06-1999 |
| 38 | 98/39035 | PCT | The Wistar Institute of Anatomy & Biology | 09-11-1998 |
| 39 | 97/05250 | PCT | University of Helsinki | 02-13-1997 |

RECEIVED
DEC 27 2007
TC 1700

Laetse 9/6/05

| | | | | |
|----|----------|-----|--|------------|
| 40 | 98/24811 | PCT | ZymoGenetics, Inc. | 06-11-1998 |
| | | | Other Documents | |
| 41 | | | ACHEN <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor-3 (Flt4)," <i>Proc. Natl. Acad. Sci. (USA)</i> , 95(2): 548-553 (1998). | |
| 42 | * | | Alderson, R. F., Yourey, P. A., and Su, J. Y. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. Keystone Symposia, Ocular Cell and Molecular Biology, 202. (Abstract provided) | retina |
| 43 | | | ANDERSSON <i>et al.</i> , "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16): 11260-11266 (1992). | |
| 44 | | | ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992). | |
| 45 | | | APRELIKOVA <i>et al.</i> , "Flt4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter," <i>Cancer Research</i> , 52: 746-748 (1992). | |
| 46 | | | BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression <i>in vitro</i> and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986). | |
| 47 | | | BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000). | |
| 48 | | | BERSE <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Mol. Biol. Cell.</i> , 3:211-220 (1992). | |
| 49 | | | BETSHOLTZ <i>et al.</i> , "cDNA Sequence and Chromosomal Localization of Human Platelet-Derived Growth Factor A-Chain and Its Expression in Tumor Cell Lines," <i>Nature</i> , 320(24): 695-699 (1986). | |
| 50 | | | BREIER <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation," <i>Development</i> , 114:521-532 (1992). | |
| 51 | | | CLAFFEY <i>et al.</i> , "Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> , 267(23): 16317-16322 (1992) | |
| 52 | | | COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> , 159:113-160 (1995). | |
| 53 | | | CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> , 17:476-484 (1993). | |
| 54 | | | DIGNAM <i>et al.</i> , "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990). | |
| 55 | | | EICHMANN <i>et al.</i> , "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," <i>Development</i> , 125(4): 743-752 (1998). | |
| 56 | | | FERRARA <i>et al.</i> , "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins," <i>Endocrine Rev.</i> , 13(1): 18-32 (1992). | |
| 57 | | | FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991). | |
| 58 | | | FINNERTY <i>et al.</i> , "Molecular Cloning of Murine FLT and FLT4," <i>Oncogene</i> , 8(11):2293-2298 (1993). | |
| 59 | | | FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> , 2:93-98 (1992). | |

Leisel

9/6/05



| | | | |
|----|----|---|--|
| 60 | pk | GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> , 121(4): 931-943 (1993). | |
| 61 | | GEORGE <i>et al.</i> , "Current methods in sequence comparison and analysis," <i>Macromolecular Seq. and Syn. Selected Meth - Application</i> (Alan R. Liss), pp. 127-149 (1998). | |
| 62 | | GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993). | |
| 63 | | GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> , 6:124-131 (1996). | |
| 64 | | GUZMAN <i>et al.</i> , "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> , 73:1202-1207 (1993). | |
| 65 | | HELDIN <i>et al.</i> , "Structure of Platelet-Derived Growth Factor: Implications for Functional Properties," <i>Growth Factors</i> , 8:245-252 (1993) | |
| 66 | | HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> , 128:423-429 (1993). | |
| 67 | | HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> , 11: 498-504 (1997). | |
| 68 | | HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993). | |
| 69 | | JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> , 15(2): 290-298 (1996). | |
| 70 | | JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911(1997). | |
| 71 | | KAIPAINEN <i>et al.</i> , "The Related FLT4, FLT1 and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," <i>J. Exp. Med.</i> , 178:2077-2088 (1993). | |
| 72 | | KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993). | |
| 73 | | KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> , 246: 1309 (1989) | |
| 74 | | KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993). | |
| 75 | | KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> , 122: 3829-37 (1996). | |
| 76 | | LEE <i>et al.</i> , "Vascular Endothelial Growth Factor-Related Protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93: 1988-1992 (1996). | |
| 77 | | LEUNG <i>et al.</i> , "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen," <i>Science</i> , 246: 1306-1309 (1989). | |
| 78 | | LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129. | |
| 79 | pk | MAGLIONE <i>et al.</i> , "Isolation of a Human Placenta cDNA Coding for a Protein Related to the Vascular Permeability Factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88: 9267-9271 (1991). | |
| 80 | | MAGLIONE <i>et al.</i> , "Two Alternative mRNAs Coding for the Angiogenic Factor, Placenta Growth Factor (PIGF) are transcribed from a single gene of Chromosome 14," <i>Oncogene</i> , 8:925-931 (1993). | |
| 81 | | MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell. Biol.</i> 6: 597-641 (1990). | |


Law 9/6/05

considered
do not
35'10"
no def

| | | | |
|-----|-----------|---|--------|
| 82 | <i>ml</i> | MATTHEWS et al., "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991). | |
| 83 | | MILLAUER et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Fik-1 mutant," <i>Nature</i> , 367: 576-579 (1994). | |
| 84 | | MILLAUER et al., "High Affinity VEGF binding and developmental expression suggest Fik-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> , 72: 835-846 (1993). | |
| 85 | | PAJUSOLA et al., "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Res.</i> , 52: 5738-5743 (1992). | |
| 86 | | PAJUSOLA et al., "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993). | |
| 87 | | PAULSSON et al., "The balbiani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> , 211: 331-349 (1990). | |
| 88 | | SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990). | |
| 89 | | SILINS et al., "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997). | |
| 90 | | STEWART et al., "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993). | |
| 91 | | TANAKA et al., "DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes," <i>Mol. Cell. Biol.</i> , 7(5): 1978-1983 (1987). | |
| 92 | | TERMAN et al., "Identification of New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," <i>Oncogene</i> , 6: 1677-1683 (1991). | |
| 93 | | TERMAN et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> , 187(3): 1579-1586 (1992). | |
| 94 | | TISCHER et al., "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comms.</i> 165(3): 1198-1206 (1989). | |
| 95 | | TISCHER, et al., "The human gene for vascular endothelial growth factor. Multiple Protein Forms are Encoded through Alternative Exon Splicing," <i>J. Biol. Chem.</i> , 266(18): 11947-11954 (1991). | |
| 96 | | TOWNSON et al., "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> 220: 922-928 (1996). | |
| 97 | | TSUJIMOTO et al., "Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci (USA)</i> , 83: 5214-5218 (1986). | |
| 98 | | WALSH et al., "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300 (1993). | |
| 99 | <i>ml</i> | WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> , 306(2): 129-136 (1993). | |
| 100 | <i>ml</i> | Yourey, P. A., Gohari, S., Su, J. Y. and Alderson, R. F. (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788. | retina |

Lavie 9/6/05

| | | | |
|-----|---|---|--------|
| 101 |  | Yourey, P. A., Gohari, S., and Alderson, R. F., (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. Soc. Cell Biology, 227. (Abstract provided) | retina |
| 102 | | GenBank Accession No. AJ000185, ACHEN et al., "Vascular endothelial growth factor-D." February 11, 1998. | |
| 103 | | GenBank Accession No. D88689, FINNERTY et al., "Mus musculus mRNA for fit-1, complete cds," April 14, 2000. | |
| 104 | | GenBank Accession No. K03212, ANDERSSON et al., "Human c-src-1 proto-oncogene exon 6." January 13, 1995. | |
| 105 | | GenBank Accession No. K03213, ANDERSSON et al., "Human c-src-1 proto-oncogene exon 7." January 13, 1995. | |
| 106 | | GenBank Accession No. K03214, ANDERSSON et al., "Human c-src-1 proto-oncogene exon 8." January 13, 1995. | |
| 107 | | GenBank Accession No. K03215, ANDERSSON et al., "Human c-src-1 proto-oncogene exon 9." January 13, 1995. | |
| 108 | | GenBank Accession No. K03216, TANAKA et al., "Human c-src-1 proto-oncogene exon 10." January 13, 1995. | |
| 109 | | GenBank Accession No. K03217, TANAKA et al., "Human c-src-1 proto-oncogene exon 11." January 13, 1995. | |
| 110 | | GenBank Accession No. K03218, TANAKA et al., "Human c-src-1 proto-oncogene exon 12." January 13, 1995. | |
| 111 | | GenBank Accession No. L04947, TERMAN et al., "Homo sapiens (clones BT3.081.0, BT3.129.5, and BT4.169) receptor tyrosine kinase (KDR) mRNA, 3' end cds." January 6, 1995. | |
| 112 | | GenBank Accession No. L07296, FINNERTY et al., "Mus musculus receptor tyrosine kinase (FLT4) mRNA," August 9, 1993.. | |
| 113 | | GenBank Accession No. L19896, CORSON et al., "Human fibrillin (FBN1) gene, 5' end including alternative exons A, B, C, and exon M." November 8, 1994. | |
| 114 | | GenBank Accession No. L22473, OLTVAI et al., "Human Bax alpha mRNA, complete cds." December 15, 1993. | |
| 115 | | GenBank Accession No. L22474, OLTVAI et al., "Human Bax beta mRNA, complete cds." December 15, 1993. | |
| 116 | | GenBank Accession No. M13994, TSUJIMOTO et al., "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds." October 31, 1994. | |
| 117 | | GenBank Accession No. M13995, TSUJIMOTO et al., "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds." October 31, 1994. | |
| 118 | | GenBank Accession No. M16237, TANAKA et al., "Human c-src-1 proto-oncogene exon 2." January 13, 1995. | |
| 119 | | GenBank Accession No. M16243, TANAKA et al., "Human c-src-1 proto-oncogene exon 3." January 13, 1995. | |
| 120 | | GenBank Accession No. M16244, TANAKA et al., "Human c-src-1 proto-oncogene exon 4." January 13, 1995. | |
| 121 | | GenBank Accession No. M16245, TANAKA et al., "Human c-src-1 proto-oncogene exon 5." January 13, 1995. | |
| 122 | | GenBank Accession No. M24160, DIGNAM et al., "C. tentans 185-kD secretory protein (sp185) mRNA, partial cds, clone pC1185." April 26, 1993. | |
| 123 |  | GenBank Accession No. M24276, DIGNAM et al., "C. tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pC1140.1." April 26, 1993. | |



9/6/05

| | | |
|-----|-----------|---|
| 124 | <i>ml</i> | GenBank Accession No. M24277, DIGNAM et al., "C. tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCI140.2," April 26, 1993. |
| 125 | | GenBank Accession No. M27281, KECK et al., "Vascular Permeability Factor mRNA, Complete cds." August 3, 1993. |
| 126 | | GenBank Accession No. M63971, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 1." August, 1993. |
| 127 | | GenBank Accession No. M63972, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 2." August, 1993. |
| 128 | | GenBank Accession No. M63973, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 3." August, 1993. |
| 129 | | GenBank Accession No. M63974, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 4." August, 1993. |
| 130 | | GenBank Accession No. M63975, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 5." August, 1993. |
| 131 | | GenBank Accession No. M63976, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 6." August, 1993. |
| 132 | | GenBank Accession No. M63977, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 7." August, 1993. |
| 133 | | GenBank Accession No. M63978, TISCHER et al., "Human Vascular endothelial growth factor gene, exon 8." August, 1993. |
| 134 | | GenBank Accession No. M95200, CLAFFEY et al., "Mouse vascular endothelial growth factor mRNA, complete cds." April 27, 1993. |
| 135 | | GenBank Accession No. S57152, MAGLIONE et al., "Placenta growth factor 2 (PlGF-2 specific exon 6)." March 5, 2001. |
| 136 | | GenBank Accession No. X04571, BELL et al., "Human mRNA for kidney epidermal growth factor (EGF) precursor." March 21, 1995. |
| 137 | | GenBank Accession No. X52263, PAULSSON et al., "C. tentans balbiani ring 3 (BR3) gene." December 18, 1992. |
| 138 | | GenBank Accession No. X54936, MAGLIONE et al., "H. sapiens mRNA for placenta growth factor (PlGF)," November 12, 1991. |
| 139 | | GenBank Accession No. X59397, MATTHEWS et al., "Mouse FLK-1 mRNA for a tyrosine kinase receptor." November 6, 1991. |
| 140 | | GenBank Accession No. X63556, CORSON et al., "H. sapiens mRNA for fibrillin." February 17, 1997. |
| 141 | | GenBank Accession No. X68203, APRELIKOVA et al., "H. sapiens mRNA for FLT4, Class III Receptor Tyrosine Kinase." November 30, 1993. |
| 142 | | International Search Report, Application No. PCT/US94/05291. |
| 143 | | International Search Report, Application No. PCT/US99/05021. |
| 144 | | Statutory Declaration of Peter Adrian Walton Rogers, and exhibit 1. |
| 145 | | Statutory Declaration of Kari Alitalo, and exhibits 1-3 (02/2000). |
| 146 | | Statutory Declaration of Francis John Ballard and exhibit 1. |
| 147 | | Statutory Declaration of Kari Alitalo, and exhibits 1-2 (09/2001). |
| 148 | | NOT INCLUDED: |
| 149 | | Statutory Declaration of John Stanley Mattick, and Exhibits JSM1-JSM4. |
| 150 | | Statutory Declaration of Nicholas Kim Hayward, and Exhibits NKH1-2. |
| 151 | | Statutory Declaration of Jennifer Ruth Gamble and Exhibits JRG1-3. |
| | | Statutory Declaration of Tom Rapoport and Exhibits TP1-2. |
| 152 | | Statutory Declaration of Stuart A. Aaronson and Curriculum Vitae of Stuart A. Aaronson. |
| 153 | | Statutory Declaration of Susan Power, Appendices 1-2 and Figure 1. |
| 154 | | Statutory Declaration of Gary Baxter Cox and Exhibits GBC-1 - GBC 23. |
| 155 | | |
| 156 | | |
| 157 | | |

continued - do not print



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|---------|
| Sheet | 1 | of | 1 | Attorney Docket Number | PF112U1 |
|-------|---|----|---|------------------------|---------|

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/499,468-Conf. #1320 |
| Filing Date | February 7, 2000 |
| First Named Inventor | Ralph Alderson |
| Art Unit | 1647 |
| Examiner Name | R. S. Landsman |
| Attorney Docket Number | PF112U1 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
|-----------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS


| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------------------|--------------------------|---|----------------|
| RL | HR | VALE et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGL1 (VEG2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation</i> (Supplement), 100(18):I.22 (Nov. 2, 1999) | |
| | HS | European Supplementary Search Report, Application No. EP 01 96 3814, mailed July 14, 2004 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--------|
| Examiner Signature | | Date Considered | 9/6/05 |
|-----------------------|--|--------------------|--------|

Considered -
do not
print



PTO/SB/083/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| | | | | Application Number | 09/499,468-Conf. #1320 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Filing Date | February 7, 2000 |
| | | | | First Named | Ralph Alderson |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | R. S. Landsman |
| | | | | Attorney Docket Number | PF112U1 |
| Sheet | 1 | of | 2 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|---------------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ | Number ⁴ -Kind Code ⁵ (if known) | | | | |
| AL | HT | WO-01/58956-A3 | | 08-16-2001 | BASF Aktiengesellschaft | | |
| | HU | WO-01/57226-A1 | | 08-09-2001 | Millennium Pharmaceuticals, Inc. | | |
| | HV | WO-00/73430-A3 | | 12-07-2000 | Max-Delbrueck Centrum Fur Molekulare Medizin | | |
| | HW | WO-99/20749 | | 04-29-1999 | Medical Research Council | | |
| | HX | WO-99/02545 | | 01-21-1999 | Novopharm Biotech, Inc. | | |
| | HY | WO-98/55619 | | 12-10-1998 | ASAT AG Applied Science & Technology | English translation of abstract only | |
| | HZ | WO-97/19694 | | 06-05-1997 | Amgen, Inc. | | |
| | IA | WO-97/08320 | | 03-06-04 | Morphosys Gesellschaft Fur Proteinoptimierung MBH | | |
| | IB | WO-97/00271 | | 01-03-1997 | The Regents of the University of California | | |
| | IC | WO-95/24473 | | 12-14-1995 | Human Genome Sciences, Inc. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AL | ID | EBI Accession No. AAW27553, KNAPPIK et al., "Human Ab heavy chain variable region VH3 consensus" (Jan. 23, 1998). | |
| AL | IE | GERHARDINGER, et al., "Expression of Vascular Endothelial Growth Factor in the Human Retina and in Nonproliferative Diabetic Retinopathy," <i>Am. J. Pathol.</i> , 152(6):1453-1462 (Jun. 6, 1998). | |
| AL | IF | LITWIN et al., "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129 (1995). | |
| | IG | Supplementary European Search Report, Application No. EP 02 72 6730, mailed October 25, 2004. | |
| | IH | Supplementary European Search Report, Application No. EP 00 90 5992, mailed November 8, 2004. | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 9/6/05 |
|--------------------|--|-----------------|--------|

considered -
do not
print



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|---------------------------|------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/499,468-Conf. #1320 |
| | | | | Filing Date | February 7, 2000 |
| | | | | First Named | Ralph Alderson |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | R. S. Landsman |
| Sheet | 2 | of | 2 | Attorney Docket Number | PF112U1 |

| | | | |
|-----------|----|--|--|
| <i>AL</i> | II | WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," P.S.E.B.M. 204: 289-300 (1993). | |
| <i>AL</i> | IJ | YANG <i>et al.</i> , "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," <i>J. Neuroscience</i> , 16(19):6089-6099 (Oct. 1, 1996). | |
| <i>AL</i> | IK | YOUREY <i>et al.</i> , "Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells," <i>Molecul. Biol. Cell</i> , 10(Suppl.):39a (Nov. 1999) and 39 th Ann. Mtg. Am. Soc. Cell Biol., Wash, DC, (Dec. 11-15, 1999) (abstract (227) only). | |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|-----------------|--------------------|--------|
| Examiner Signature | <i>Landsman</i> | Date Considered | 9/6/05 |
|-----------------------|-----------------|--------------------|--------|